Tyra Biosciences, Inc. Debt Securities, Available-for-sale, Amortized Cost
Tyra Biosciences, Inc. (TYRA) had Debt Securities, Available-for-sale, Amortized Cost of $280.69 million as of 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Notes › Credit Losses
us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis · last filed 2026-08-04
- 2026-06-30: Debt Securities, Available-for-sale, Amortized Cost $280.69M.
- 2026-03-31: Debt Securities, Available-for-sale, Amortized Cost $298.40M.
- 2025-12-31: Debt Securities, Available-for-sale, Amortized Cost $178.22M.
- 2025-09-30: Debt Securities, Available-for-sale, Amortized Cost $212.53M.
| Period end | Debt Securities, Available-for-sale, Amortized Cost |
|---|---|
| 2026-06-30 | $280.69M 10-Q · filed 2026-08-04 |
| 2026-03-31 | $298.40M 10-Q · filed 2026-05-13 |
| 2025-12-31 | $178.22M 10-Q · filed 2026-08-04 |
| 2025-09-30 | $212.53M 10-Q · filed 2025-11-05 |
| 2025-06-30 | $197.34M 10-Q · filed 2025-08-14 |
| 2025-03-31 | $217.53M 10-Q · filed 2025-05-08 |
| 2024-12-31 | $248.71M 10-K · filed 2026-03-02 |
| 2024-09-30 | $254.49M 10-Q · filed 2024-11-07 |
| 2024-06-30 | $274.49M 10-Q · filed 2024-08-07 |
| 2024-03-31 | $128.10M 10-Q · filed 2024-05-09 |
| 2023-12-31 | $145.08M 10-K · filed 2025-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |